RESUMEN
PURPOSE: We evaluated the rate of prostate cancer detection using the transrectal ultrasound(TRUS) guided, 41-core prostate needle biopsy protocol. MATERIALS AND METHODS: Between May 2006 and May 2007, 110 patients received a 12-core prostate needle biopsy(Group I) and 62 patients underwent a 41-core prostate needle biopsy(Group II) under local anesthesia. In addition to sextant biopsy, 41-core prostate needle biopsies were obtained from the each lateral peripheral zone(base, mid, and apex glands), midline peripheral zone(base, mid, and apex glands) and each transition zone. RESULTS: There were no significant differences between the two groups for age, prostate-specific antigen(PSA), or prostate volume. The cancer detection rate in the Group I and Group II was 19.1% and 24.2%, respectively. We found a significantly higher detection rate in the 41-core biopsy with prostate volumes of more than 40cc(28.1% vs 11.3%). The intraoperative pain score was lower in Group II than Group I(1.57+/-1.45 vs 3.17+/-1.73, p<.01). CONCLUSIONS: The 41-core prostate needle biopsy protocol is safe and intraoperative pain is low. The cancer detection rate of the 41-core prostate needle biopsy was higher than the 12-core prostate needle biopsy in patients with a prostate volume of more than 40cc.